ALLO-316

N/A

Report date: 2024/04/26 11:46:45

Base Information

Drug NameALLO-316
Drug Alias NameAlloCAR T™ Therapy (Allogene Therapeutics)Anti-CD70 CAR T cell therapy (Allogene Therapeutics)CD70 targeted CAR-T cell therapy (Allogene Therapeutics)AlloCAR T™ (Allogene Therapeutics)ALLO-316
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsCarcinoma, Renal CellLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCellectis SaOverland Pharmaceuticals (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAllogene Therapeutics IncOverland Pharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal CellLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A